Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

07.02.2019 | case report

The path of an esophageal carcinoma patient from curative to palliative treatment

memo - Magazine of European Medical Oncology
MD Ercan Müldür, Karl Mayrhofer, Wolfgang Hilbe
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


We hereby report the course and management of a patient with human epidermal growth factor receptor 2 negative esophageal cancer who received neoadjuvant chemoradiation, surgical resection and subsequently palliative therapy for recurrent disease. The critical role of the staging procedure is discussed. Additionally the options of systemic palliative therapies are presented and the rationale for immuno-oncologic treatment is highlighted. The patient received pembrolizumab as second-line therapy, which unfortunately did not result in a response and caused minor autoimmune side effects.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Über diesen Artikel